Related references
Note: Only part of the references are listed.Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Brian T. Hopkins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
Eric Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Shape Complementarity Optimization of Antibody-Antigen Interfaces: The Application to SARS-CoV-2 Spike Protein
Alfredo De Lauro et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2022)
Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity
Hui Qiu et al.
CHEMMEDCHEM (2021)
Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development
Jiakuo Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The Development of BTK Inhibitors: A Five-Year Update
Bruno Tasso et al.
MOLECULES (2021)
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Danling Gu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA-induced breast cancer cell invasion via PLCγ2/PKCβ/NF-κB/AP-1-dependent matrix metalloproteinase-9 activation
Jeong-Mi Kim et al.
ONCOLOGY REPORTS (2021)
Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors
Jiamin Zheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Discovery of potent and selective reversible Bruton?s tyrosine kinase inhibitors
Hui Qiu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review
Michael Stack et al.
CLINICAL IMMUNOLOGY (2021)
The role of Bruton's tyrosine kinase in the immune system and disease
Charlotte McDonald et al.
IMMUNOLOGY (2021)
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design
Mark Sabat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Datong Zhang et al.
MOLECULES (2021)
Targeting Bruton's Tyrosine Kinase in CLL
Inhye E. Ahn et al.
FRONTIERS IN IMMUNOLOGY (2021)
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
Rula Zain et al.
FRONTIERS IN IMMUNOLOGY (2021)
Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies
Katharine L. Lewis et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Stefan F. H. Neys et al.
DRUGS (2021)
Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations
Angus T. Voice et al.
CHEMICAL SCIENCE (2021)
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
Tingyu Wen et al.
LEUKEMIA (2021)
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Daniela Angst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
Clare Sun et al.
BLOOD (2020)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Wei Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George et al.
CANCERS (2020)
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
Bin Ma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a] pyrazine core featuring 3-position bicyclic ring substitutes
Jian Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Ling Xiao et al.
CIRCULATION (2020)
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity
James J. Crawford et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy
Jingcheng Zhang et al.
SCIENTIFIC REPORTS (2020)
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
Raji E. Joseph et al.
ELIFE (2020)
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells
Yueh Pan et al.
ANTICANCER RESEARCH (2020)
Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies
Fabienne Lucas et al.
TARGETED ONCOLOGY (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
Jennifer Woyach et al.
BLOOD (2019)
BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis
Shipra Das et al.
ONCOGENE (2019)
Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
Jasper Rip et al.
FRONTIERS IN IMMUNOLOGY (2019)
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Oshrat Hershkovitz-Rokah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
NF-kappa B Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy
Paula Grondona et al.
BIOMEDICINES (2018)
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Nisar A. Amin et al.
CLINICAL CANCER RESEARCH (2017)
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
T. Seiler et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties
Xiaojing Wang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Alexander N. R. Weber et al.
FRONTIERS IN IMMUNOLOGY (2017)
Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia
Lian Xu et al.
BLOOD (2017)
AKT/PKB Signaling: Navigating the Network
Brendan D. Manning et al.
CELL (2017)
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Andrew J. Gunderson et al.
CANCER DISCOVERY (2016)
The PI3K pathway in B cell metabolism
Julia Jellusova et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2016)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Atish Mohanty et al.
ONCOTARGET (2016)
Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib
Jiaji G. Chen et al.
BLOOD (2016)
Integration of signaling in the kinome: Architecture and regulation of the αC Helix
Susan S. Taylor et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2015)
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells
Vaclav Seda et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma
Sophie Bernard et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Toll-like receptors in the pathogenesis of human B cell malignancies
Johana M. Isaza-Correa et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
David Chiron et al.
CANCER DISCOVERY (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Potential roles of activation-induced cytidine deaminase in promotion or prevention of autoimmunity in humans
Anne Durandy et al.
AUTOIMMUNITY (2013)
Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment
Jianyi Yang et al.
BIOINFORMATICS (2013)
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
Robbert Hoogeboom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The complexity of NF-κB signaling in inflammation and cancer
Bastian Hoesel et al.
MOLECULAR CANCER (2013)
Targeting pathological B cell receptor signalling in lymphoid malignancies
Ryan M. Young et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sandrine Sander et al.
CANCER CELL (2012)
The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Laurens P. Kil et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
Jan A. Burger
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
The Src, Syk, and Tec family kinases: Distinct types of molecular switches
J. Michael Bradshaw
CELLULAR SIGNALLING (2010)
Complementarity in biology A reassessment in relation to molecular-reductionist and systemic approaches
Fulvio Mazzocchi
EMBO REPORTS (2010)
A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen
Petra J. ter Brugge et al.
BLOOD (2009)
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
Marta Muzio et al.
BLOOD (2008)
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia
Liguang Chen et al.
BLOOD (2008)
B Cell receptor directs the activation of NFAT and NF-κB via distinct molecular mechanisms
P Antony et al.
EXPERIMENTAL CELL RESEARCH (2003)
NF-kappa B activation by protein kinase C isoforms and B-cell function
J Moscat et al.
EMBO REPORTS (2003)
Share Paper
